JBS UNDERSTANDS THE CHALLENGES AND HAS THE KNOW-HOW TO CONFRONT THEM

Crack cocaine in the mid-1980s. The rise of steroids, ecstasy, and crystal meth in the 1990s and early 2000s. The skyrocketing use of prescription painkillers (opioids) and heroin. Since our founding, we have been on the frontlines, responding to every major drug epidemic that has plagued all of our states and territories.

TAKE A DEEPER LOOK AT WHAT SETS JBS APART...

Our unparalleled team of experts focuses daily on vulnerable populations, and national, state, and local systems to address the full spectrum of substance abuse and its impact on society.
Amplified by a passionate “dream team” of experts in the substance abuse field, JBS is effecting change at every major crossroad of the opioid epidemic.

**OUR INDUSTRY-RECOGNIZED EXPERTS**

**Joyce Dampeer, PhD, MS, Corporate Monitor & Senior Principal**
- 28 years of experience as a licensed clinical psychologist specializing in substance abuse and mental health services
- Expertise in crisis intervention; trauma and family violence; family-centered treatment; and medication-assisted treatment (MAT)
- Technical assistance (TA) expert for the Substance Abuse and Mental Health Services Administration (SAMHSA) pregnant and postpartum women (PPW) and adolescent grantees program
- Provides TA on family-centered treatment that includes mothers, children, fathers, and other family members

**Susan Hayashi, PhD, Vice President/Project Director**
- JBS Vice President with 20 years of experience addressing opioid issues
- Expertise in research and evaluation; medical education; communication targeting medical professional organizations and medical schools; and TA and training related to prescription medication misuse, overdose, safe prescribing, and MAT
- Contributing author for a 2017 *Journal of Addiction Medicine* article on pregnant and parenting opioid-dependent women and their children
- Supports multiple SAMHSA projects (including telehealth initiatives, the Criminal Justice/MAT Policy Academy, and analytic work on increasing patient limits for buprenorphine prescribing)
- Led a National Institute on Drug Abuse (NIDA) continuing medical education (CME) course on adolescent substance use

**Jennifer Kasten, PhD, MSW, Chief Strategy Officer**
- 35 years of experience as a clinician in the behavioral health field
- Expertise in substance abuse prevention, intervention, and treatment
- Planned and conducted SAMHSA’s “Physician Training for Use of Buprenorphine” in multiple states
- Developed and conducted behavioral health provider trainings on pharmacotherapies for addictive disorders for the Connecticut Department of Mental Health and Addictive Disorders Counselor Training Program, and the states of Vermont and Rhode Island
- Worked with clinics and healthcare programs throughout the United States that support substance use disorder service integration in primary care

**Joyce Dampeer, PhD, MS, Corporate Monitor & Senior Principal**
- JBS Vice President and former clinician with 25 years of experience in the behavioral health field
- Expertise in substance abuse prevention, intervention, and treatment
- Led the Center for Substance Abuse Treatment (CSAT) Clinical TA Project (including the 2014 assessment of Opioid Treatment Programs and Services for PPW) since 2009
- Co-author of *Methadone Maintenance Treatment in the United States: A Practical Question and Answer Guide*

**Joseph Hyde, MA, LMHC, CAS, Technical Expert Lead**
- 34 years of experience as a researcher in the substance abuse field
- Expertise in research translation, design, and implementation
- Serves as a Technical Expert Lead to SAMHSA’s Division of Services Improvement (DSI) Clinical TA adolescent grant program
- Developed the Comprehensive Adolescent Severity Inventory (CASI), an adolescent-specific multi-dimensional assessment that examines adolescent functioning
- Former Senior Research Scientist for the Center on Families and Adolescents at the Treatment Research Institute (TRI)
- Led the translation of scientific findings into usable products that enhance clinical treatment
More than 30 years of experience with adults and adolescents with mental health and substance use disorders in residential and outpatient settings (in both the public and private sectors)
- Expertise in clinical and administrative processes, program design, and implementation
- Serves as a Technical Expert Lead for SAMHSA’s Clinical TA portfolio focused on adolescent and transition-aged youth grantees
- Former trainer for the NIDA–SAMHSA Blending Initiative on Buprenorphine Treatment for Multidisciplinary Addiction Professionals
- Designed, implemented, and completed activities to secure state licensure and provided counseling and case management services for a start-up office-based buprenorphine practice

• JBS Vice President with 38 years of experience in the behavioral health field
- Directs SAMHSA’s inaugural State TA Project (since 2012), and was Project Director for CSAT’s State Systems Technical Assistance Project for 14 years
- Managed the delivery of nearly 2,000 training and TA activities for behavioral health delivery systems in all 50 states and in territories
- Officer-in-Charge of the SAMHSA/CSAT Knowledge Application Program, a project that develops and disseminates information on best practices in substance abuse treatment

• 31 years of experience in prevention and treatment of substance use disorders; and mental health disorders.
- Expertise in the development and implementation of models of care for opioid use disorder including treatment, post-treatment, and recovery supports.
- Oversaw the West Virginia State Opioid Treatment Authority, Women’s Coordinator, and the state’s prevention and treatment system

• Co-Director of JBS’s Center for Sustainable Health and Care
- More than 25 years of experience in integrating behavioral health and primary care, and more than 15 years of experience in federal policy directions for expanding Health IT use (including telehealth, information exchange and technology use in person-centered care, and adoption of value-based payment models)
- Serves as a Technical Expert Lead for SAMHSA’s Technology-Assisted Care discretionary grant portfolio
- Project Director of the Office of the National Coordinator for Health Information Technology
- Emerging Issues Project, which developed policy, educational materials, and health IT tools in support of behavioral health providers (including opioid treatment organizations)
- Previously served in state agency leadership positions addressing mental health and substance use services in Texas

• More than 20 years of experience working with culturally diverse, marginalized, and underserved populations in the fields of public health, chronic disease management, and wellness
- Expertise in project implementation; opioid overdose prevention; implementing MAT; and relapse and recidivism
- Serves as a Technical Expert Lead for Criminal Justice (CJ) Programs for the SAMHSA’s CSAT, DSI Clinical TA project
- Addresses public health and criminal justice systems’ challenges at the local, state, and federal levels
TAKE A DEEPER LOOK AT WHAT SETS US APART.

Below is a sampling of JBS’s opioid-related projects:

---

**CME/CE Training for Healthcare Providers**
- DSI CJ – MAT Regional Training: Drug Court and MAT Successes
- Addressing Opioid-related Misuse and Overdose (AOMO) – Clinical Challenges in Opioid Prescribing: Balancing Safety and Efficacy
- NIDA – Adolescent Substance Use and Rx Medication Misuse CME/CE
- Naloxone Overdose Prevention and Education Program

**Integration of Primary Care and Behavioral Health**
- SAMHSA Buprenorphine Summit, MAT and Benzodiazepine Meeting, and a U.S. Department of Health and Human Services Tele-Substance Use Treatment Working Group
- Outreach and Education to Healthcare Providers on Substance Use – 12 Curriculum Resources

**Healthcare Workforce Development**
- DSI Adolescent – “Opioid Use Disorders (OUD): What Pediatricians Should Know” publication
- AOMO – Small, regional trainings with medical professionals to provide training to fight the opioid epidemic and OUD
- State TA Prescriber Guidelines (PA)
- Opioid Treatment Program Quality (OTP-Q) – Support OTP accreditation/certification and conduct medical education training in eight states per year

**Outreach to Vulnerable Populations**
- Journal of Addiction Medicine publication (2017): “Treating women who are pregnant and postpartum for opioid use disorders and the concurrent care of their infants and children: Literature review to support national guidance”
- MAT-PDOA webinar: MAT in Correctional Settings

**Improved Access to Care**
- MAT-PDOA online course: Overcoming Barriers to Prescribing Buprenorphine
- AOMO TA: State of Hawaii sustainability planning

**State TA for expanding MAT through mobile services (in CO, DC, NV, OK, and PR)**
**State TA at multi-state meetings on Expanding Access and Opioid-Related Overdose Policies and Practices**

**Understanding of Medication-Assisted Treatment**
- Social marketing campaigns to overcome resistance to MAT (in GA, KY, NY, OK, and VT)

**Program Evaluation**
- DSI PPW – Treatment Programs and Services for Pregnant and Postpartum Women: A Program Evaluation
- State TA Data Collection for Prevention of Non-Medical Use of Prescription Opioids (in NM)

---

For more information contact: info@jbsinternational.com or call 301.495.1080

---

www.jbsinternational.com

---

JBS INTERNATIONAL

MARYLAND
5515 Security Lane
Suite 800
North Bethesda, MD
20852-5002

CALIFORNIA
555 Airport Boulevard
Suite 400
Burlingame, CA
94010-2002

GEORGIA
3 Corporate Boulevard, NE
Suite 100
Atlanta, GA
30329-2013